Company identity
Company number 03888792
Company profile
UK company 03888792, incorporated on 6 December 1999.
Home | GSK
At GSK, we unite science, technology and talent to get ahead of disease together
Company number 03888792
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzUzNzUzOTg1NmFkaXF6a2N4
Published 07 Aug 2026 11:23
CS01 | Transaction MzUzNjA1MjYwOGFkaXF6a2N4
Published 31 Jul 2026 08:45
Last confirmation statement made up date
SH01 | Transaction MzUzMTQ3OTU3MWFkaXF6a2N4
Published 09 Jul 2026 12:05
SH03 | Transaction MzUyNzQ5NTc0NWFkaXF6a2N4 | Paper/PDF filed
Published 03 Jul 2026 00:47
SH01 | Transaction MzUyNzc4OTQzN2FkaXF6a2N4
Published 22 Jun 2026 14:27
SH03 | Transaction MzUyMzcxNjQzMWFkaXF6a2N4 | Paper/PDF filed
Published 09 Jun 2026 23:08
MA | Transaction MzUyMTUyMTI1NGFkaXF6a2N4 | Paper/PDF filed
Published 25 May 2026 22:31
RESOLUTIONS | Transaction QUYxVUE1MTZhZGlxemtjeA | Paper/PDF filed
Published 25 May 2026 22:31
RESOLUTIONS | Transaction WUYxSzlTMkFhZGlxemtjeA | Paper/PDF filed
Published 25 May 2026 22:31
Last accounts made up date
Company registered at Companies House
1 Nov 2024 to 31 Oct 2027
To employ recent statistical innovations and introduce 'trial emulation' into the drug development process within pharmaceutical industry leader GSK to help design future research and accelerate access to drugs. Emulated trials use available data enabling faster exploration of hypotheses for new treatments without the need for a new clinical trial.
6 Apr 2023 to 6 Apr 2025
The project will deliver significant improvements in speed and quality of pharmaceutical product manufacturing processes. This will be achieved through an embedded understanding of the impact of pressure on polymorphs in active pharmaceutical ingredients (APIs), which impacts product stability and biopharmaceutics, ultimately resulting in increased profit...
1 Dec 2020 to 30 Nov 2023
Currently, there are no disease-modifying treatments that can prevent or slow down PD. PD, like other neurodegenerative conditions, is a disorder involving both genetic (e.g. _PINK1_ and _Parkin_ genes) and environmental factors (e.g. age, pesticides). Recently, multiple regions of PD patient's DNA were found to be different to those not having the diseas...
1 Dec 2020 to 30 Nov 2023
The project herein involves evaluating whether AI and other digital tools can improve understanding of how to progress tuberculosis science to mitigate its global burden. Tuberculosis is the leading global infectious threat and the poor are disproportionately affected. With the increasing burden of HIV-tuberculosis co-infections, tuberculosis has become a...
1 Jul 2020 to 30 Jun 2022
New therapeutic products in the pharma industries are invariably large, complex chemical molecules -- e.g., synthetic active ingredients, amino acids, peptides etc. In the consumer goods and food industries, complex emulsions form the backbone of products such as detergents, beauty products, milk and other liquid-based foods. An essential pre-requisite fo...
1 May 2020 to 31 Oct 2022
Public description Industrial Digital Technologies (IDT's) are disrupting industries across the globe. The breadth and depth of these changes herald the transformation of entire systems of production, management, and governance. There is overwhelming evidence that IDTs can provide a step change in industrial productivity(2). The Smart Connected Factory is...
1 Mar 2020 to 31 Aug 2022
.
1 Oct 2019 to 30 Sep 2021
To transform both the depth and quality of consumer driven insights into brand perception, captured by the Shopper Science Laboratory, using a suite of novel interactive Augmented Reality technologies, leading to new product creation and a wider market share.
1 Aug 2019 to 31 Mar 2020
Awaiting Public Project Summary
1 Feb 2019 to 31 Mar 2023
"The London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare will improve NHS patient care and health outcomes, reduce healthcare costs and support the growth of companies, supporting the economy. It will do this by applying artificial intelligence technologies to medical imaging (for example MRI scans, CT scans PET scans and ul...
1 Apr 2018 to 30 Sep 2021
Awaiting Public Project Summary
1 Feb 2018 to 31 Jan 2020
The project will develop a new, rapid and non-destructive test instrument for predicting tablet efficacy and performance, based on direct measurements of tablet porosity using terahertz light. In so doing, we expect to contribute to manufacturing efficiency improvements in production of advanced solid dose medicines. Our technology will initially be marke...